OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sandler on Guideline Compliant Care

March 30th 2011

Howard M. Sandler, MD, MS from Cedars-Sinai Medical Center, on Guideline Compliant Care

Dr. Dreicer on Prostate Cancer Combination Therapy

March 29th 2011

Robert Dreicer, MD, from the Taussig Cancer Institute, discusses the various treatments that prostate cancer patients may receive in combination.

Dr. Sandler on Candidates for Liase Inhibitor Clinical Trials

March 29th 2011

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials.

Traditional LHRH Agonists Versus Newer Drugs

March 29th 2011

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies

Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties

March 28th 2011

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

Dr. Kris on the EML4-ALK Translocation in Lung Cancer

March 25th 2011

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation

Dr. Tew Evaluates Avastin Treatment in Ovarian Cancer

March 24th 2011

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

Dr. Kris on the Crizotinib Clinical Trials

March 23rd 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on the Crizotinib Clinical Trials

Dr. Pecora Discusses Value-Based Healthcare

March 22nd 2011

Andrew L. Pecora, MD, Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, discusses his thoughts on a value-based healthcare system.

Dr. Kris on Caring for Elderly Lung Cancer Patients

March 22nd 2011

Dr. Mark G. Kris from Memorial Sloan-Kettering on Caring for Elderly Lung Cancer Patients

Dr. Kris Discusses EGFR Mutation Testing

March 21st 2011

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York Discusses EGFR Mutation Testing

Dr. Alter on Trials and Ongoing Research in Kidney Cancer

March 21st 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Dr. Pearlstone on Ongoing Research in Breast Cancer

March 16th 2011

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

Dr. Jabbour on Front-Line Treatments for CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Dr. Jabbour on Second-Generation TKIs in CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.

Vandetanib Advantages in Medullary Thyroid Cancer

March 15th 2011

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

March 15th 2011

Dr. Langmuir Discusses Vandetanib Clinical Trials

March 15th 2011

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Dr. Pecora on his Personal Involvement in Research

March 15th 2011

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Dr. Berenson on the Study of Zometa in Multiple Myeloma

March 15th 2011

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.